NCT02737956

Brief Summary

This study aims to establish a registry and surveillance system for acute myocardial infarction (AMI) patients in Xinjiang, focusing on collecting comprehensive information including basic patient demographics, patient characteristics, diagnostic methods, treatment programs, and hospitalization outcomes such as mortality, treatment complications, hospitalization costs, and follow-up events (death, major adverse cardiac events). The goal is to identify and propose effective prevention strategies to reduce the incidence of AMI, optimize the management and outcomes of AMI patients by implementing guideline recommendations in clinical practice, and conduct analyses to develop effective treatment strategies and predictive models for clinical outcomes. This focus on Xinjiang aims to provide a comprehensive understanding of AMI within this specific geographic and demographic context, ultimately contributing to improved prevention, treatment, and management of AMI patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7,350

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

April 5, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 14, 2016

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2016

Completed
7.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2023

Completed
Last Updated

March 28, 2024

Status Verified

March 1, 2024

Enrollment Period

4 years

First QC Date

April 5, 2016

Last Update Submit

March 26, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Death

    All-cause mortality, Cardiac mortality

    5 years

Secondary Outcomes (3)

  • Major adverse cardiovascular events (MACE)

    5 years

  • Major adverse cardiovascular and cerebrovascular events (MACCE)

    5 years

  • stroke

    5 years

Study Arms (2)

AMI patients with treatment of PCI

All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.

Medication

All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population consists of acute myocardial infarction (AMI) patients hospitalized at the First Affiliated Hospital of Xinjiang Medical University. This includes individuals diagnosed with both acute ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).

You may qualify if:

  • Acute myocardial infarction patients in hospitalized of the First Affiliated Hospital of Xinjiang Medical University (include diagnosed acute ST-elevation or non ST-elevation myocardial infarction).Diagnosis criteria must meet Universal Definition for AMI (2012).

You may not qualify if:

  • Combined with severe valvular heart disease;
  • Combined with severe congenital heart disease;
  • Combined hyperthyroidism, anemia and other high-powered heart disease;
  • With pulmonary heart disease;
  • With hypertrophic obstructive cardiomyopathy;
  • Severe hypotension (SBP \<90mmHg or DBP \<60mmHg at enrollment);
  • Uncontrolled hypertension (SBP\> 160 mmHg before PCI, and / or DBP\> 100 mmHg);
  • Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times);
  • Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit);
  • High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases;
  • active peptic ulcer and skin ulcers;
  • A patient who is allergic to clopidogrel, tegrellol, or aspirin;
  • Patients with a history of cardiogenic shock within two weeks;
  • pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age;
  • In the past 3 months participated in other clinical researchers;
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affilliatted Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830011, China

Location

Related Publications (2)

  • Yan J, Deng CJ, Wang SF, Aimaitijiang M, Wu TT, Zheng YY, Xie X, Ma YT. Predictive Value of the Modified GRACE Scoring System for All-Cause Mortality in Patients with Acute Myocardial Infarction. Rev Cardiovasc Med. 2023 Jun 6;24(6):161. doi: 10.31083/j.rcm2406161. eCollection 2023 Jun.

  • Xiu WJ, Yang HT, Zheng YY, Ma YT, Xie X. Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study. J Interv Cardiol. 2019 Jun 18;2019:2387929. doi: 10.1155/2019/2387929. eCollection 2019.

Study Officials

  • Xiang Xie, PhD

    Xinjiang Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Xiangxie, MD,Professor, The First Affiliated Hospital Of XinJiang Medicial University

Study Record Dates

First Submitted

April 5, 2016

First Posted

April 14, 2016

Study Start

June 1, 2012

Primary Completion

May 31, 2016

Study Completion

December 10, 2023

Last Updated

March 28, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations